Alan Wade

Summary

Affiliation: Disaster Mental Health Institute

Publications

  1. ncbi Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data
    Alan G Wade
    CPS Research, Glasgow, UK
    Pharmacoeconomics 26:969-81. 2008
  2. ncbi Urinary flow and urinary symptoms in elderly males exposed to either escitalopram or duloxetine
    Alan G Wade
    CPS Research, Glasgow, UK
    Curr Med Res Opin 26:1031-5. 2010
  3. ncbi A multicentre, randomised, double-blind, single-dose study assessing the efficacy of AMC/DCBA Warm lozenge or AMC/DCBA Cool lozenge in the relief of acute sore throat
    Alan G Wade
    CPS Research, Glasgow, UK
    BMC Fam Pract 12:6. 2011
  4. ncbi Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study
    Alan G Wade
    CPS Research, Glasgow, G20 0XA, UK
    BMC Psychiatry 11:42. 2011
  5. ncbi Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response
    A G Wade
    CPS Research, Glasgow, Scotland, UK
    Psychol Med 41:2089-97. 2011
  6. ncbi Antidepressant treatment and cultural differences--a survey of the attitudes of physicians and patients in Sweden and Turkey
    Alan G Wade
    BMC Fam Pract 11:93. 2010
  7. ncbi Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response
    Alan G Wade
    CPS Research, Glasgow, UK
    Curr Med Res Opin 27:87-98. 2011
  8. ncbi Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety
    Alan G Wade
    CPS Research, Glasgow, UK
    BMC Med 8:51. 2010
  9. ncbi Healthcare expenditure in severely depressed patients treated with escitalopram, generic SSRIs or venlafaxine in the UK
    Alan G Wade
    CPS Clinical Research Centre, Glasgow, UK
    Curr Med Res Opin 26:1161-70. 2010
  10. ncbi Prolonged-release melatonin for the treatment of insomnia in patients over 55 years
    Alan Wade
    CPS Research, 3 Todd Campus, West of Scotland Science Park, Glasgow, G20 0KA, Scotland
    Expert Opin Investig Drugs 17:1567-72. 2008

Detail Information

Publications16

  1. ncbi Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data
    Alan G Wade
    CPS Research, Glasgow, UK
    Pharmacoeconomics 26:969-81. 2008
    ..In addition, escitalopram has been shown to be cost saving compared with venlafaxine...
  2. ncbi Urinary flow and urinary symptoms in elderly males exposed to either escitalopram or duloxetine
    Alan G Wade
    CPS Research, Glasgow, UK
    Curr Med Res Opin 26:1031-5. 2010
    ..To profile the effects of escitalopram with duloxetine on urinary flow rate and symptoms in elderly males aged 55-75 years...
  3. ncbi A multicentre, randomised, double-blind, single-dose study assessing the efficacy of AMC/DCBA Warm lozenge or AMC/DCBA Cool lozenge in the relief of acute sore throat
    Alan G Wade
    CPS Research, Glasgow, UK
    BMC Fam Pract 12:6. 2011
    ....
  4. ncbi Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study
    Alan G Wade
    CPS Research, Glasgow, G20 0XA, UK
    BMC Psychiatry 11:42. 2011
    ..Escitalopram is licensed for use at doses up to 20 mg but is used clinically at higher doses. There is limited published data at higher doses and none in the treatment of Major Depressive Disorder (MDD)...
  5. ncbi Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response
    A G Wade
    CPS Research, Glasgow, Scotland, UK
    Psychol Med 41:2089-97. 2011
    ..The purpose of this study was to compare citalopram 40 mg once daily plus pipamperone 5 mg twice daily (PipCit) versus citalopram plus placebo twice daily for magnitude and onset of therapeutic effect...
  6. ncbi Antidepressant treatment and cultural differences--a survey of the attitudes of physicians and patients in Sweden and Turkey
    Alan G Wade
    BMC Fam Pract 11:93. 2010
    ..This study was conducted to compare the presenting symptoms and response to antidepressant medication of patients in Sweden and Turkey, two culturally different European countries...
  7. ncbi Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response
    Alan G Wade
    CPS Research, Glasgow, UK
    Curr Med Res Opin 27:87-98. 2011
    ....
  8. ncbi Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety
    Alan G Wade
    CPS Research, Glasgow, UK
    BMC Med 8:51. 2010
    ....
  9. ncbi Healthcare expenditure in severely depressed patients treated with escitalopram, generic SSRIs or venlafaxine in the UK
    Alan G Wade
    CPS Clinical Research Centre, Glasgow, UK
    Curr Med Res Opin 26:1161-70. 2010
    ..To retrospectively compare the 12-month healthcare utilisation and direct medical costs associated with the use of escitalopram, generic SSRIs, and venlafaxine in patients with severe depression in the United Kingdom (UK)...
  10. ncbi Prolonged-release melatonin for the treatment of insomnia in patients over 55 years
    Alan Wade
    CPS Research, 3 Todd Campus, West of Scotland Science Park, Glasgow, G20 0KA, Scotland
    Expert Opin Investig Drugs 17:1567-72. 2008
    ..However, until now treatment of insomnia has primarily targeted quantity of sleep. PR (prolonged release)-melatonin offers a new treatment option in insomnia...
  11. ncbi Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes
    Alan G Wade
    CPS Research, Glasgow, UK
    Curr Med Res Opin 23:2597-605. 2007
    ..The efficacy and safety of a prolonged release melatonin formulation (PR-melatonin; Circadin* 2 mg) were examined in insomnia patients aged 55 years and older...
  12. ncbi Escitalopram in the long-term treatment of major depressive disorder
    Alan Wade
    CPS Research, Glasgow, United Kingdom
    Ann Clin Psychiatry 18:83-9. 2006
    ..The long-term clinical tolerability and response to treatment are presented from a 12-month open-label study with a total exposure time to escitalopram of 486 patient years...
  13. ncbi The onset of effect for escitalopram and its relevance for the clinical management of depression
    Alan Wade
    CPS Clinical Research Centre, Glasgow, UK
    Curr Med Res Opin 22:2101-10. 2006
    ..To analyse the significance of 'onset of effect' on clinical outcome in the treatment of depression and the contribution of individual Montgomery-Asberg Depression Rating Scale (MADRS) items to improvements in the MADRS total score...
  14. ncbi A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care
    Alan Wade
    Community Pharmacology Services Ltd CPS, Clydebank, Glasgow, UK
    Int Clin Psychopharmacol 18:133-41. 2003
    ....
  15. ncbi A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK
    Alan G Wade
    CPS Research, Glasgow, UK
    Curr Med Res Opin 21:631-42. 2005
    ..Robustness of findings was assessed in multivariate sensitivity analyses. CONCLUSION: In primary care in the UK, escitalopram is cost-effective compared with citalopram and quite similar to venlafaxine in treating MDD...
  16. ncbi A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom
    Alan G Wade
    CPS Research, Glasgow, United Kingdom
    Clin Ther 27:486-96. 2005
    ..Therefore, a possible advantage may exist at the population level in the treatment of severe depression with escitalopram in the United Kingdom...